Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial.
Edward M KerwinIsabelle H BoucotClaus F VogelmeierFrancois MaltaisIan P NayaLee TombsPaul W JonesDavid A LipsonTom KeeleyLeif BjermerPublished in: Therapeutic advances in respiratory disease (2021)
NCT03034915, 2016-002513-22 (EudraCT Number). The reviews of this paper are available via the supplemental material section.